Related Experiment Video
Updated: Apr 5, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
11.0K
Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations
M Ponsford1, E Carne1, C Kingdon1
1Immunodeficiency Centre for Wales, Department of Immunology.
Clinical and Experimental Immunology
|August 20, 2015
Summary
Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIg) offers a well-tolerated alternative for primary antibody deficiency, with high patient satisfaction and improved delivery compared to traditional methods. Practical considerations are key for successful implementation.
Area of Science:
- Immunology
- Pharmacology
Background:
- Primary antibody deficiency requires immunoglobulin replacement therapy.
- Available options include intravenous immunoglobulin (IVIg) and various subcutaneous immunoglobulin (SCIg) methods.
- Recombinant human hyaluronidase-facilitated SCIg (fSCIg) is a newer modality with potential advantages.
Purpose of the Study:
- To describe the initial real-world experience with fSCIg in 14 patients.
- To evaluate the practical aspects, tolerability, and patient satisfaction with fSCIg.
- To provide guidance on implementing fSCIg therapy.
Main Methods:
- Retrospective case series of 14 patients treated with fSCIg.
- Assessment of tolerability, adverse events, and patient satisfaction.
- Ultrasound imaging to compare subcutaneous distribution between conventional and facilitated SCIg.
Main Results:
- fSCIg was generally well-tolerated with high patient satisfaction over 6 patient-years.
- Two patients discontinued due to local reactions; one paused due to migraines.
- Ultrasound showed enhanced subcutaneous distribution with fSCIg, enabling higher infusion rates and volumes.
Conclusions:
- fSCIg is a viable and satisfactory treatment option for primary antibody deficiency.
- Careful consideration of administration parameters (pump, needle, site, training) is crucial for successful fSCIg implementation.
- fSCIg offers advantages in delivery efficiency and patient convenience over traditional IVIg and SCIg.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
1.1K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.1K
01:25Routes of Drug Administration: Parenteral
3.8K
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
3.8K